United Therapeutics Corporation ($UTHR) Stock Forecast: Down 5.2% Today

What is United Therapeutics Corporation?

United Therapeutics Corporation (UTHR) is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. The company's stock had a strong bearish movement today.

Why is United Therapeutics Corporation going down?

UTHR stock is down 5.2% on Apr 2, 2026 14:21

• The bearish movement in UTHR's stock could be attributed to the significant insider selling by the director, Christopher Causey, who exercised stock options and sold shares at a much higher price, possibly signaling lack of confidence in the stock's future performance.
• Despite positive news like successful Phase 3 trials and analyst price target increases, the insider selling coupled with concerns raised by institutional investors like Retirement Systems of Alabama might have contributed to the downward pressure on the stock.
• The proposed sale of additional shares through a stock option exercise by UTHR could have added to the selling pressure, creating a bearish sentiment among investors.
• The overall market reaction might have been influenced by profit-taking activities following the recent surge in stock price fueled by positive study results, as investors reevaluate the stock's valuation and potential downside risks highlighted.

UTHR Price Chart

UTHR Technical Analysis

UTHR News

UNITED THERAPEUTICS (UTHR) director exercises options and sells 1,300 shares under 10b5-1 plan

Christopher Causey, a director at UNITED THERAPEUTICS Corp (UTHR), exercised stock options for 1,300 shares at $119.76 per share and simultaneously sold 1,300 shares at $604.64 per share. These transactions, executed on March 30, 2026, were pre-planned under a Rule 10b5-1 trading plan established on September 30, 2025. Following these trades, Causey directly holds 4,190 shares of Common Stock.

https://www.stocktitan.net/sec-filings/UTHR/form-4-united-therapeutics-corp-insider-trading-activity-15be529d9ccf.html

Retirement Systems of Alabama Has $47.39 Million Stock Holdings in United Therapeutics Corporation $UTHR

Retirement Systems of Alabama reduced its holding in United Therapeutics Corporation (NASDAQ:UTHR) by 3.0% in Q4, now owning 97,268 shares valued at $47.39 million. Despite positive news like successful Phase 3 trials and board-authorized buybacks, which have led to analyst price target increases, significant insider selling from the CEO and CFO raises investor concern. Institutional investors collectively own 94.08% of the company's stock.

https://www.marketbeat.com/instant-alerts/filing-retirement-systems-of-alabama-has-4739-million-stock-holdings-in-united-therapeutics-corporation-uthr-2026-03-31/

United Therapeutics Corp (UTHR) Stock Price Up 13.08% on Mar 30

United Therapeutics Corp (UTHR) stock surged by 13.08% in mid-day trading on March 30, reaching an intraday high of $607.89 before closing at $591.21. This places the stock just below its 52-week high, with a significant increase from its 52-week low. Wall Street analysts provide an average target price of $592.80, suggesting an "Outperform" status, although GuruFocus estimates a potential downside based on its GF Value.

https://www.gurufocus.com/news/8756601/united-therapeutics-corp-uthr-stock-price-up-1308-on-mar-30?mobile=true

United Therapeutics (NASDAQ: UTHR) proposed sale of 1,300 shares via option

United Therapeutics Corporation (NASDAQ: UTHR) has filed a Form 144 notice indicating a proposed sale of 1,300 shares of common stock through a stock option exercise scheduled for March 30, 2026. The filing also details prior open-market dispositions by Christopher Causey in early 2026. This regulatory notice transparently outlines the intent to sell these shares.

https://www.stocktitan.net/sec-filings/UTHR/144-united-therapeutics-corp-sec-filing-a10f887e9730.html

United Therapeutics Rises on Positive Study for Cornerstone Drug. Why Shares Could Run Even Higher.

United Therapeutics Corp. (UTHR) saw its shares rise significantly on Monday following positive results from a second Phase 3 clinical trial. The study focused on a nebulized version of its primary drug, Tyvaso, highlighting improved outcomes. This development suggests potential for further growth in the stock.

https://www.barrons.com/articles/united-therapeutics-positive-study-cornerstone-drug-078a729f?gaa_at=eafs&gaa_n=AWEtsqfG2hmwHEiSNk0xI4HV3iVKbzcK4Lz2lLBwEW43TDs2bYC84mQAhwtt&gaa_ts=69caaaf9&gaa_sig=D5ZFRHdwqF7OiwJgZilrBSMEaoBJm7YbBT7N9uxNvXpQTJRtM8KuDk0MfFb7QERfp8iXjwLgHcZNruaCJF7lwg%3D%3D

Trending Today

Crude Oil ($CRUDE) Commodity Forecast: Up 5.8% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Up 5.2% Today

Heating Oil ($HEATOIL) Commodity Forecast: Up 6.2% Today

Wingstop Inc. ($WING) Stock Forecast: Down 5.6% Today

Five Below Inc. ($FIVE) Stock Forecast: Down 5.4% Today

Upstart Holdings Inc. ($UPST) Stock Forecast: Down 5.1% Today

Reddit Inc ($RDDT) Stock Forecast: Down 5.8% Today

Silver ($XAG) Commodity Forecast: Down 5.0% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 5.2% Today

Teleflex Incorporated ($TFX) Stock Forecast: Down 5.1% Today

United Therapeutics Corporation Price History

06.00.2026 - UTHR Stock was up 5.0%

• Today's positive movement in UTHR stock is linked to the company's Chairperson and CEO speaking at the J.P. Morgan Healthcare Conference, underlining their dedication to innovation and addressing medical needs.
• Institutional investors, including Merit Financial Group LLC and Allspring Global Investments Holdings LLC, have increased their stake in the company, showing confidence in its future growth despite recent insider transactions.
• An analysis of the rotational strategy timing suggests short-term sentiment may be weak. However, the focus remains on UTHR's long-term potential and fundamentals, indicating investors are looking beyond immediate fluctuations.

02.03.2026 - UTHR Stock was down 5.2%

• The bearish movement in UTHR's stock could be attributed to the significant insider selling by the director, Christopher Causey, who exercised stock options and sold shares at a much higher price, possibly signaling lack of confidence in the stock's future performance.
• Despite positive news like successful Phase 3 trials and analyst price target increases, the insider selling coupled with concerns raised by institutional investors like Retirement Systems of Alabama might have contributed to the downward pressure on the stock.
• The proposed sale of additional shares through a stock option exercise by UTHR could have added to the selling pressure, creating a bearish sentiment among investors.
• The overall market reaction might have been influenced by profit-taking activities following the recent surge in stock price fueled by positive study results, as investors reevaluate the stock's valuation and potential downside risks highlighted.

01.07.2025 - UTHR Stock was up 5.1%

• The reasons for the bullish movement in UTHR stock are:
• Strong Tyvaso sales contributing to a 12% increase in revenues year-over-year.
• Despite missing earnings estimates for the second quarter, the market reacted positively to the company's revenue growth.
• The announcement of a share repurchase program of up to $1 billion by the company's board may have instilled confidence in investors concerning future prospects.
• Investors seem to be concentrating more on the revenue growth and potential of the company's product portfolio rather than short-term earnings misses.

10.02.2026 - UTHR Stock was up 5.6%

• UTHR experienced strong bullish movement following the announcement of a new $2 billion stock repurchase program, which includes a $1.5 billion Accelerated Share Repurchase (ASR) program with Citibank. This strategic move demonstrates confidence in the company's growth potential and belief in the undervaluation of its stock, leading to heightened investor confidence.
• The share repurchase agreements aim to decrease outstanding shares, potentially increasing the company's earnings per share and delivering value to shareholders. This capital allocation decision was well-received by investors, contributing to the rise in the stock price.
• Through these buyback programs, United Therapeutics is not only improving shareholder value but also utilizing its robust balance sheet to pursue long-term goals. The market's positive response to this shareholder-friendly initiative indicates optimism regarding UTHR's future performance.

03.02.2026 - UTHR Stock was down 5.3%

• Price targets for UTHR were raised by Jefferies and other firms after the positive Phase 3 trial results of its drug ralinepag for PAH treatment, showing a 55% reduction in clinical worsening risk.
• Despite the encouraging trial outcomes and analyst positivity, UTHR's stock saw a bearish movement, possibly attributed to profit-taking following recent gains.
• The company's recent product launches and advancements in xenotransplantation may have played a role in its robust stock performance over the previous year, although today's market movement could be influenced by broader market conditions or technical factors.
• Investors are advised to monitor UTHR's upcoming FDA submission for ralinepag and its revenue targets for potential future catalysts.

26.01.2026 - UTHR Stock was down 5.5%

• UTHR shares dropped by nearly 5% as the company missed Q4 revenue estimates while surpassing earnings expectations. This discrepancy could raise concerns among investors regarding the company's future growth trajectory.
• The company's operating margin declined year-on-year, indicating potential issues in cost management or operational efficiency that may have contributed to the market's negative response.
• Insider trading activities by the President and COO, involving the sale of shares at a specific price, could have impacted market sentiment, leading to a bearish trend as investors analyzed this move.
• Even though UTHR's Tyvaso product line and strategic efforts performed well, the market's attention on the revenue miss and insider trading overshadowed the positive financial results, causing a decline in the stock price.

25.01.2026 - UTHR Stock was up 11.2%

• The positive stock movement in UTHR is possibly linked to insider trading by President and COO Michael Benkowitz, who recently exercised stock options and sold shares at a noteworthy price, signaling confidence in the company's performance.
• Investors are looking forward to the upcoming Q4 earnings report, expecting a year-over-year revenue growth despite previous revenue estimate misses. This anticipation could potentially drive the stock price up.
• The FDA's recent approval of Tyvaso dry powder inhaler for treating PAH and PH-ILD, a product developed by United Therapeutics, may have influenced investor sentiment positively. This showcases the company's dedication to innovation and addressing unmet medical needs in the market.

02.08.2025 - UTHR Stock was up 0.8%

• Following the announcement of an expanded collaboration with MannKind Corporation for a second inhaled therapy, United Therapeutics (UTHR) witnessed a notable increase in its stock price. This development likely instilled confidence in investors regarding the company's growth potential and the possibility of new revenue streams.
• The positive market response could also be linked to the upcoming earnings report of United Therapeutics, adding to the optimistic outlook for the company's financial performance. As the stock continues to rise, investors appear hopeful about its future prospects.
• Today's bullish movement in UTHR's stock reflects the favorable progress in collaboration initiatives and the market's optimistic view of the company's future in the pharmaceutical sector.

30.02.2026 - UTHR Stock was up 0.5%

• The positive phase 3 study results for nebulized Tyvaso and the introduction of a new $2 billion stock repurchase program have driven the bullish movement in United Therapeutics' stock, receiving favorable attention from analysts and investors.
• Initial concerns surrounding insider selling by company executives, including the CEO, Chairperson, COO, and CFO, were potentially offset by increased institutional investor stake from Wealth Enhancement Advisory Services LLC and Wedge Capital Management L L P NC.
• A price target raise by Cantor Fitzgerald to $625 with an "Overweight" rating has further bolstered investor confidence in the company, in anticipation of the upcoming TETON-1 clinical trial for idiopathic pulmonary fibrosis treatment.
• While revenue fell short of estimates, a strong performance in earnings per share during Q4, along with strategic initiatives and a positive outlook, likely played a role in the recent bullish trend of United Therapeutics' stock.

30.06.2025 - UTHR Stock was down 5.4%

• UTHR reported Q2 earnings that missed analyst estimates on both the top and bottom lines, leading to a bearish movement in the stock.
• The company's announcement of a share repurchase program of up to $1 billion did not seem to offset the disappointment from the earnings miss.
• The stock crossing above the 50-day moving average could have initially signaled a positive trend, but the earnings results likely overshadowed this technical indicator, causing the bearish movement.
• Investors may be concerned about the company's future performance based on the Q2 results, leading to a sell-off in the stock.

29.09.2025 - UTHR Stock was up 8.3%

• UTHR experienced a strong bullish movement today by surpassing Q3 earnings estimates, exceeding expectations by 3.92%.
• The anticipation of earnings growth leading up to the upcoming report has likely bolstered the positive sentiment, showcasing faith in the company's future performance.
• Investors appear hopeful about UTHR's prospects, given its consistent delivery of favorable outcomes and ability to meet market expectations, resulting in an increase in the stock price.

29.09.2025 - UTHR Stock was up 9.7%

• UTHR stock showed a strong bullish movement today, likely influenced by the company surpassing Q3 earnings expectations.
• Despite revenues falling below projections, the robust performance of Tyvaso and Orenitram contributed to the positive earnings surprise.
• Investor optimism regarding potential growth opportunities in the coming quarters may be fueled by the earnings beat.
• Market trends indicate that investors are more focused on the positive earnings surprise and growth potential, overshadowing the revenue shortfall and driving the bullish momentum in UTHR stock.